Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan · Delayed Price · Currency is TWD 46.00
-2.00 (-4.17%)
At close: Jul 29, 2026
Pet Pharm Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Income | 24.99 | 14.51 | 9.15 | -3.81 |
Depreciation & Amortization | 32.99 | 18.28 | 16.67 | 14.23 |
Other Amortization | 1.6 | 1.33 | 0.08 | 0.07 |
Loss (Gain) From Sale of Assets | - | - | - | 0.21 |
Asset Writedown & Restructuring Costs | - | - | - | 0.1 |
Stock-Based Compensation | 0.62 | 0.02 | 0.01 | - |
Provision & Write-off of Bad Debts | 0.02 | -0.03 | -1.2 | 1.2 |
Other Operating Activities | -0.91 | -2.32 | - | - |
Change in Accounts Receivable | -19.02 | -2.51 | -9.13 | -8.53 |
Change in Inventory | 0.97 | -2.88 | -4.99 | -1.33 |
Change in Accounts Payable | -13.67 | 3.11 | 1.9 | -4.3 |
Change in Unearned Revenue | 0.51 | 0.37 | 0.85 | -0.24 |
Change in Other Net Operating Assets | 6.21 | -0.97 | 7.43 | -15.42 |
Operating Cash Flow | 34.3 | 28.88 | 20.75 | -17.83 |
Operating Cash Flow Growth | 18.75% | 39.16% | - | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Capital Expenditures | -29.51 | -188.4 | -12.68 | -10.04 |
Sale of Property, Plant & Equipment | - | - | - | 1.5 |
Cash Acquisitions | -107.11 | - | - | - |
Sale (Purchase) of Intangibles | -0.37 | -1.08 | - | - |
Investment in Securities | -44 | -65 | -91 | -50 |
Other Investing Activities | -220.63 | -8.46 | -30.1 | 0.48 |
Investing Cash Flow | -401.61 | -262.93 | -133.77 | -58.07 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Long-Term Debt Issued | 1.58 | 100 | - | - |
Short-Term Debt Repaid | - | - | - | -4.05 |
Long-Term Debt Repaid | -109.38 | -7.03 | -5.25 | -3.78 |
Total Debt Repaid | -109.38 | -7.03 | -5.25 | -7.82 |
Net Debt Issued (Repaid) | -107.8 | 92.97 | -5.25 | -7.82 |
Issuance of Common Stock | 567.03 | 162.42 | 270 | 96.5 |
Common Dividends Paid | -5.05 | -8.04 | - | - |
Other Financing Activities | 0.01 | - | - | - |
Financing Cash Flow | 454.18 | 247.35 | 264.75 | 88.68 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Net Cash Flow | 86.87 | 13.3 | 151.73 | 12.78 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 4.79 | -159.51 | 8.08 | -27.87 |
Free Cash Flow Growth | - | - | - | - |
Free Cash Flow Margin | 2.16% | -122.05% | 6.85% | -36.80% |
Free Cash Flow Per Share | 0.09 | -3.85 | 0.27 | -1.11 |
Levered Free Cash Flow | -2.7 | -25.09 | -84.79 | - |
Unlevered Free Cash Flow | -2.14 | -24.98 | -84.69 | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash Interest Paid | 0.88 | 0.18 | 0.18 | 0.2 |
Cash Income Tax Paid | 0.08 | 0.1 | - | - |
Change in Working Capital | -25 | -2.89 | -3.95 | -29.82 |